Trials / Completed
CompletedNCT07018492
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
A Phase 1, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of BPN14770 in Participants With Mild, Moderate, and Severe Hepatic Impairment and Healthy Control Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPN14770 | Administered as specified in the treatment arm. |
Timeline
- Start date
- 2025-08-30
- Primary completion
- 2025-11-26
- Completion
- 2025-11-26
- First posted
- 2025-06-12
- Last updated
- 2026-02-27
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07018492. Inclusion in this directory is not an endorsement.